SCHEMBL4363232

SCHEMBL4363232

CN1CCc2c(-c3ccc(Cl)cc3)ccc([N+](=O)[O-])c2C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.51
HTR2C P28335 3/20 0.51
HTR2B P41595 1/20 0.51
GRIA1 P42261 3/20 0.44
GRIA2 P42262 3/20 0.44
GRIA3 P42263 3/20 0.44
GRIA4 P48058 3/20 0.44
POLB P06746 2/20 0.41
LMNA P02545 1/20 0.41
ALDH1A1 P00352 3/20 0.40
GAA P10253 1/20 0.40
HTR6 P50406 3/20 0.39
DRD2 P14416 2/20 0.39
DRD3 P35462 2/20 0.39
MAPK1 P28482 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
CYP1A2 P05177 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6614736 0.87 HTR2A (0.45) HTR2AHTR2CHTR2BGRIA1GRIA2
SCHEMBL6613450 0.87 HTR2A (0.47) HTR2AHTR2CHTR2BGRIA1GRIA2
SCHEMBL6608151 0.84 GRIA1 (0.45) HTR2AHTR2CHTR2BGRIA1GRIA2
SCHEMBL8134137 0.81 GRIA1 (0.43) HTR2AHTR2CHTR2BGRIA1GRIA2
SCHEMBL8137079 0.79 ALDH1A1 (0.48) GRIA1GRIA2GRIA3GRIA4POLB
Hydrochloric Acid SCHEMBL4377355 0.76 MEN1 (0.41) HTR2AHTR2CGRIA1GRIA2GRIA3
SCHEMBL3020938 0.75 HTR2A (0.51) HTR2AHTR2CHTR2BGRIA1GRIA2
SCHEMBL8189050 0.75 HTR2A (0.51) HTR2AHTR2CHTR2BGRIA1GRIA2
SCHEMBL10605219 0.72 HTR2A (0.66) HTR2AHTR2CHTR2BGRIA1GRIA2
SCHEMBL14287479 0.71 GRIA1 (0.46) GRIA1GRIA2GRIA3GRIA4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595336-B2 Isatine derivatives with neurotrophic activity NEUROSEARCH A/S (DK) 2009-09-29 US disclosed
US-7282511-B2 Isatine derivatives with neurotrophic activity NEUROSEARCH A/S (DK) 2007-10-16 US disclosed
EP-1736468-A2 Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation NeuroSearch A/S (DK) 2006-12-27 EP disclosed
US-20060229311-A1 Isatine derivatives with neurotrophic activity GROENBORG METTE 2006-10-12 US disclosed
EP-1255734-B1 ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY NEUROSEARCH AS (DK) 2006-06-21 EP disclosed
EP-0869958-B1 NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES NEUROSEARCH AS (DK) 2004-12-29 EP disclosed
EP-1066037-B1 USE OF INDOLE-2,3-DIONE-3-OXIME DERIVATIVES AS AMPA ANTAGONISTS NEUROSEARCH AS (DK) 2004-12-29 EP disclosed
US-6693111-B1 1H-PYRROLO(3,2-H)ISOQUINOLINE DERIVATIVES; EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS NEUROSEARCH A/S (DK) 2004-02-17 US disclosed
US-RE38200-E1 Capable of antagonizing effect of excitatory amino acids, such as glutamate NEUROSEARCH A/S (DK) 2003-07-22 US disclosed
US-20030040518-A1 Isatine derivatives with neurotrophic activity ANIONA APS (DK) 2003-02-27 US disclosed
US-5917053-A INHIBITING GABA RELEASE FROM NEURONS NEUROSEARCH A/S (DK) 1999-06-29 US disclosed
US-5843945-A AMPA antagonists and a method of treatment NEUROSEARCH A/S (DK) 1998-12-01 US disclosed
EP-0869958-A1 NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES NEUROSEARCH A/S (DK) 1998-10-14 EP disclosed
US-5780493-A TREATING BRAIN DISORDERS NEUROSEARCH A/S (DK) 1998-07-14 US disclosed
WO-1998014447-A1 NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES NEUROSEARCH A/S (DK) 1998-04-09 WO disclosed
EP-0698025-B1 AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH NEUROSEARCH AS (DK) 1997-12-17 EP disclosed
EP-0781284-A1 INDOLE-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 1997-07-02 EP disclosed
WO-1996008494-A1 INDOLE-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 1996-03-21 WO disclosed
EP-0698025-A1 AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH NEUROSEARCH A/S (DK) 1996-02-28 EP disclosed
WO-1994026747-A1 AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH NEUROSEARCH A/S (DK) 1994-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229311-A1 Isatine derivatives with neurotrophic activity BDNF, NTRK2, NGF HTR2A 1309/4885HTR2C 2417/4885HTR2B 3226/4885
US-20030040518-A1 Isatine derivatives with neurotrophic activity BDNF, NTRK2, NGF HTR2A 1309/4885HTR2C 2417/4885HTR2B 3226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.